<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00646087</url>
  </required_header>
  <id_info>
    <org_study_id>04-07-04</org_study_id>
    <nct_id>NCT00646087</nct_id>
  </id_info>
  <brief_title>Ketamine Frequency Treatment for Major Depressive Disorder</brief_title>
  <official_title>Ketamine Frequency Treatment for Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Essentia Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Essentia Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Depression is a wide spread illness. Depression contributes most significantly to national
      health care costs. While the number and types of treatments used for depression have expanded
      over the years, even with an increased range of options, the response rate, defined as the
      number of subjects who have a 50% reduction in depressive symptoms, is estimated to be around
      65%.

      This randomized clinical trial will examine the frequency of treatment with ketamine in
      patients with treatment-resistant depression TRD without psychosis. It will compare two modes
      of the ketamine treatment; every other day ketamine, versus two active and four placebo
      treatments over the period of 12 days.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Pilot study determined that this study would not be feasible.
  </why_stopped>
  <start_date>March 2008</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy measure is the change in scores in the 21-item Hamilton Depression Rating Scale.</measure>
    <time_frame>20 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with remission (HDRS score &lt; 18) at the end of the 2-week treatment and each follow-up contact.</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Treatment Resistant Depression</condition>
  <arm_group>
    <arm_group_label>Ketamine (6K)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6K: 6 ketamine injections (0.5 mg/kg of ketamine) every other day for 12 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine/Placebo (2K4P)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2K4P = two active ketamine injections(2K) and four placebo (saline) injections over 12 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>0.5 mg/kg of ketamine every other day for 12 days (days 1, 3, 5, 7, 9, 11)</description>
    <arm_group_label>Ketamine (6K)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine/Saline</intervention_name>
    <description>0.5 mg/kg of ketamine on days 1 and 7, placebo (saline) on days 3, 5, 9, 11</description>
    <arm_group_label>Ketamine/Placebo (2K4P)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 30 to 65

          -  Major depressive disorder without psychotic features confirmed by a structured
             clinical diagnostic interview, SCID.

          -  Treatment resistant depression defined using the Antidepressant Treatment History Form
             (ATHF)

          -  HDRS 21 score &gt; 18

          -  Female participants of childbearing potential must be using a medically accepted means
             of contraception (birth control pills, spermicidal barrier)

          -  Ability to concur with medication standardization regiment (section as an outpatient

          -  Physically healthy (no chronic diseases; normal CBC, BMP, AST, ALT, and UA)

          -  Competent to give informed consent to all required tests and examinations and sign a
             consent document

        Exclusion Criteria:

          -  Bipolar disorder

          -  Psychosis or any other psychotic disorder as defined by DSM-IV criteria

          -  Serious or imminent threat for suicide

          -  Pregnant or nursing female

          -  Presence of serious unstable medical illnesses including hepatic, renal,
             gastrointestinal, respiratory, cardiovascular, endocrinologic, neurologic,
             immunologic, or hematologic disease, or abnormal laboratory tests (CBC, BMP, AST, ALT,
             and UA)

          -  Uncontrolled hypertension

          -  History of CVA

          -  Treatment with St. Johns wort, tramadol, phentolamine, naloxone, or anticholinergic
             medications

          -  Alcohol or illicit drug abuse for 6 months (evidence from UDS)

          -  Currently involved in a clinical trial or used an experimental medication within the
             last 30 days

          -  Hypersensitivity to ketamine products
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Micheal Messer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Essentia Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Mary's Duluth Clinic Health System</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pincus HA, Pettit AR. The societal costs of chronic major depression. J Clin Psychiatry. 2001;62 Suppl 6:5-9. Review.</citation>
    <PMID>11310818</PMID>
  </reference>
  <reference>
    <citation>Holtzheimer PE 3rd, Nemeroff CB. Advances in the treatment of depression. NeuroRx. 2006 Jan;3(1):42-56. Review.</citation>
    <PMID>16490412</PMID>
  </reference>
  <reference>
    <citation>Nierenberg AA, Amsterdam JD. Treatment-resistant depression: definition and treatment approaches. J Clin Psychiatry. 1990 Jun;51 Suppl:39-47; discussion 48-50. Review.</citation>
    <PMID>2112132</PMID>
  </reference>
  <reference>
    <citation>Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62 Suppl 16:10-17. Burrows GD, Norman TR, Judd FK. Definition and differential diagnosis of treatment-resistant depression. Int Clin Psychopharmacol. Jun 1994;9 Suppl 2:5-10.</citation>
  </reference>
  <reference>
    <citation>Burrows GD, Norman TR, Judd FK. Definition and differential diagnosis of treatment-resistant depression. Int Clin Psychopharmacol. 1994 Jun;9 Suppl 2:5-10. Review.</citation>
    <PMID>7930496</PMID>
  </reference>
  <reference>
    <citation>Crown WH, Finkelstein S, Berndt ER, Ling D, Poret AW, Rush AJ, Russell JM. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry. 2002 Nov;63(11):963-71.</citation>
    <PMID>12444808</PMID>
  </reference>
  <reference>
    <citation>Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000 Feb 15;47(4):351-4.</citation>
    <PMID>10686270</PMID>
  </reference>
  <reference>
    <citation>Correll GE, Futter GE. Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions. Pain Med. 2006 Jan-Feb;7(1):92-5.</citation>
    <PMID>16533209</PMID>
  </reference>
  <reference>
    <citation>Kudoh A, Takahira Y, Katagai H, Takazawa T. Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg. 2002 Jul;95(1):114-8, table of contents.</citation>
    <PMID>12088953</PMID>
  </reference>
  <reference>
    <citation>Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006 Aug;63(8):856-64.</citation>
    <PMID>16894061</PMID>
  </reference>
  <reference>
    <citation>Hirota K, Lambert DG. Ketamine: its mechanism(s) of action and unusual clinical uses. Br J Anaesth. 1996 Oct;77(4):441-4.</citation>
    <PMID>8942324</PMID>
  </reference>
  <reference>
    <citation>Paul IA, Skolnick P. Glutamate and depression: clinical and preclinical studies. Ann N Y Acad Sci. 2003 Nov;1003:250-72. Review.</citation>
    <PMID>14684451</PMID>
  </reference>
  <reference>
    <citation>Annetta MG, Iemma D, Garisto C, Tafani C, Proietti R. Ketamine: new indications for an old drug. Curr Drug Targets. 2005 Nov;6(7):789-94. Review.</citation>
    <PMID>16305457</PMID>
  </reference>
  <reference>
    <citation>Stewart CE. Ketamine as a street drug. Emerg Med Serv. 2001 Nov;30(11):30, 32, 34 passim. Review.</citation>
    <PMID>11759641</PMID>
  </reference>
  <reference>
    <citation>Correll GE, Maleki J, Gracely EJ, Muir JJ, Harbut RE. Subanesthetic ketamine infusion therapy: a retrospective analysis of a novel therapeutic approach to complex regional pain syndrome. Pain Med. 2004 Sep;5(3):263-75.</citation>
    <PMID>15367304</PMID>
  </reference>
  <reference>
    <citation>Leonard B. Clinical implications of mechaniszms of action of antidepresants. Advan Psychiatr Treat. 2000;6:178-186.</citation>
  </reference>
  <reference>
    <citation>Beck AT, Beamesderfer A. Assessment of depression: the depression inventory. Mod Probl Pharmacopsychiatry. 1974;7(0):151-69.</citation>
    <PMID>4412100</PMID>
  </reference>
  <reference>
    <citation>Beck AT, Steer RA, Garbin MG. Psycometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clin Psychol Rev. 1988;8:77-100.</citation>
  </reference>
  <reference>
    <citation>Overall J, Gorham D. The brief psychiatric rating scale. Psycol Rep. 1962;10:799-812.</citation>
  </reference>
  <reference>
    <citation>Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, Mazure CM. Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress. 1998 Jan;11(1):125-36.</citation>
    <PMID>9479681</PMID>
  </reference>
  <reference>
    <citation>HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62.</citation>
    <PMID>14399272</PMID>
  </reference>
  <reference>
    <citation>First MB, Spitzer RL, Miriam G, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute; 2002</citation>
  </reference>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2008</study_first_submitted>
  <study_first_submitted_qc>March 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2008</study_first_posted>
  <last_update_submitted>June 3, 2011</last_update_submitted>
  <last_update_submitted_qc>June 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2011</last_update_posted>
  <responsible_party>
    <name_title>Micheal Messer MD</name_title>
    <organization>St. Mary's Duluth Clinic Health System</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

